Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant PK in Impaired Hepatic Function
NCT04903821Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elinzanetant in vasomotor symptoms (4 arms), sponsored by Bayer. Primary endpoints: Maximum observed drug concentration at steady state at Day 8 and Area under the concentration-time curve from 0 to 24 hours at steady state. Started Jun 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04903821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903821.